Molecular Analysis of Uterine Receptivity
子宫容受性的分子分析
基本信息
- 批准号:9813937
- 负责人:
- 金额:$ 34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-04-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced DevelopmentAllelesAssisted Reproductive TechnologyBiopsyCRISPR/Cas technologyCell CompartmentationCell physiologyCellsClinicalDeciduaDecidual CellDecidual Cell ReactionsDevelopmentDiagnosisDiagnosticEmbryoEmbryonic DevelopmentEndometrialEndometrial Stromal CellEndometriumEngineeringEpithelialEpithelial CellsEventFemale infertilityFertilityFutureGene Expression ProfileGenetic TranscriptionGenomicsGoalsGrowthHigh Risk WomanHumanImpairmentIn VitroIndividualInfertilityKnowledgeMediatingMediator of activation proteinMenstrual cycleMolecularMolecular AnalysisMusNational Institute of Child Health and Human DevelopmentOocytesOutcomeOutcome StudyPhasePregnancyPregnancy lossProcessProgesteroneProgesterone ReceptorsRegulationRegulatory ElementReportingReproductive HealthRoleSignal TransductionSpontaneous abortionStromal CellsTestingTherapeuticTranscriptional RegulationUterusWomanZNF145 genebasecell typeclinically relevantclinically significantearly pregnancyfailure Implantationgene repressiongenome-wideimplantationimprovedimproved outcomein vivoinsightmouse modelnatural Blastocyst Implantationnovelpre-clinicalpregnancy failurepregnantprognosticprogramspromoterreproductiveresponsesuccesstranscription factortranscriptomeuterine receptivity
项目摘要
Project Summary
Embryo implantation failure is a significant causal factor of infertility for women worldwide. Although advances
in our understanding of oocyte and embryo development have improved pregnancy success rates, these rates
remain unacceptably low due in part to an endometrium that is nonreceptive to the embryo. For successful
implantation, endometrial receptivity and subsequent decidualization requires coordinated progesterone (P4)
signaling in a cell-type specific manner. While the signature cellular events that underpin P4-driven uterine
receptivity and decidualization are known, our knowledge of the pivotal mediators of P4 action in these
processes is incomplete. This knowledge-deficiency is significant as nothing short of identifying the key early
signals that underpin P4-driven uterine receptivity will address the current clinical limitations in diagnosing and
treating a non-receptive uterus at the molecular level. To address this deficiency, we recently demonstrated
that the promyelocytic leukemia zinc finger (PLZF) transcription factor is a direct target of the progesterone
receptor (PGR) and is indispensable for P4-dependent decidualization of cultured human endometrial stromal
cells (hESCs). As further translational support for a P4 mediator role for PLZF in the human endometrium,
PLZF expression levels in human endometrial biopsies are significantly induced during the P4-dominant
secretory phase of the human non-conception menstrual cycle. In the early pregnant mouse, Plzf is induced in
the epithelial and stromal compartments of the receptive uterus and is strongly expressed in decidual cells with
pregnancy progression. These findings support our hypothesis that PLZF (and its downstream transcriptional
program) acts as a pivotal mediator of P4-dependent uterine receptivity and decidualization and does so in an
endometrial cell-type specific manner. This hypothesis will be tested by three specific aims. Using a recently
generated mouse model carrying a Plzf conditional allele, Specific Aim 1 will establish the in vivo importance
of Plzf (and its transcriptional programs) in P4-dependent endometrial receptivity and decidualization.
Dissecting the individual contributions of epithelial and stromal Plzf signaling in the murine endometrium during
the periimplantation period will be a major focus of Specific Aim 2. We recently demonstrated that direct
transcriptional repression of the early growth response 1 (EGR1) transcription factor by PLZF is required for
hESC decidualization;; blocking this regulation impairs hESC decidualization. Prior to decidualization, however,
EGR1 in pre-decidual hESCs is required for these cells to decidualize, suggesting that EGR1 “primes” the pre-
decidual hESC for decidualization. Specific Aim 3 will address this proposal by molecularly characterizing the
P4-PGR-PLZF-EGR1 regulatory axis that is required for in vitro and in vivo decidualization. These aims will
use state-of-the-art engineered mice to study the role of Plzf in endometrial receptivity and decidualization as
well as high throughput genome-scale approaches to identify novel endometrial targets directly regulated by
Plzf and the transcriptional interactome through which this regulation occurs.
项目总结:
--
胚胎着床失败是世界范围内女性不孕不育的一个重要原因。
在我们对卵母细胞和胚胎发育的进一步了解中,妊娠率和成功率都有了很大的提高。
保持在令人无法接受的低水平,部分原因是由于子宫内膜缺乏,这是一种不能接受胚胎发育的物质。这是成功的原因之一。
着床、子宫内膜容受性下降以及随后的子宫蜕膜形成需要协调的孕酮分泌(P4)。
以一种细胞类型和特定的方式发出信号。它同时也是细胞免疫事件的标志性事件,这些事件可能支撑着P4驱动的子宫。
接受性和去中心化是未知的,因为我们对P4和行动的关键调停者的最新知识。
流程是不完整的。但这种知识缺乏的问题非常重要,因为除了及早发现关键问题之外,没有什么是不重要的。
有迹象表明,支持P4驱动的子宫内膜容受性的信号将无法解决目前在诊断卵巢癌和卵巢癌方面的临床应用限制。
在分子水平上治疗一个无法接受的子宫。为了解决这个缺陷,我们最近证明了这一点。
这就是早幼粒细胞白血病和锌指蛋白(PLZF)的转录调节因子,也是孕激素的直接靶点。
受体受体(PGR)是P4依赖的人子宫内膜间质细胞蜕膜形成过程中不可缺少的调节因子。
细胞(HESCs)。随着进一步的翻译支持,PLZF在人类正常子宫内膜中扮演着P4调节因子的角色。
PLZF在人类子宫内膜活检组织中的表达水平在P4占优势的时期被显著诱导。
在人类未受孕和月经周期的第一个阶段的分泌。在第一个早期怀孕的小鼠身上,PLZF是被诱导的。
子宫的上皮细胞和间质细胞在子宫蜕膜细胞中也有较强的表达。
怀孕和进展。这些发现将支持我们的假设,即PLZF转录(和其下游转录)。
Program)在P4依赖的子宫容受性和蜕膜化过程中扮演着关键的调停者角色,在女性中也是如此。
子宫内膜上皮细胞类型和特定的实验方式。这一假说还将通过三个特定的实验目标来检验。最近使用了一个实验。
通过携带一种有条件的PLZF等位基因,产生的小鼠模型将不会确立其在体内的重要性。
PLZF的基因(及其转录调控程序)与P4依赖的子宫内膜容受性和蜕膜化有关。
解剖小鼠子宫内膜上皮细胞和间质细胞的个体差异,提示PLZF参与了小鼠子宫内膜的发育。
围植入期计划也将成为具体计划2的一个主要重点计划。我们最近展示了这一直接计划。
PLZF基因转录和抑制早期生长反应基因(Egr1)转录调节因子的表达可能是治疗所必需的。
HESC支持去蜕膜化;;正在阻止这一监管措施,从而损害了hESC去蜕膜化。然而,在实现去蜕膜化之前,它是优先的。
蜕膜前胚胎干细胞中的Egr1基因是这些细胞完成蜕膜形成所必需的,这表明Egr1基因是蜕膜前的“质数”。
DECUDUAL:hESC支持去蜕膜化。它的具体目标是通过从分子上描述它的特征来解决这一提议。
P4--PGR--PLZF-Egr1是一条调控轴心,即体外排卵和体内蜕膜排卵都不是必需的。但这些目标将会持续下去。
使用最先进的基因工程小鼠来研究PLZF基因在提高子宫内膜容受性和促进蜕膜形成中的重要作用。
此外,还有高通量的基因组规模的检测方法,以进一步确定由基因直接调控的新的子宫内膜癌靶点。
PLZF负责并控制转录和互动组,通过该组转录和互动组,这一新的调控得以发生。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN P LYDON其他文献
JOHN P LYDON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN P LYDON', 18)}}的其他基金
PROGESTERONE RECEPTOR IN BREAST DEVELOPMENT AND CANCER
孕酮受体在乳房发育和癌症中的作用
- 批准号:
6965687 - 财政年份:1998
- 资助金额:
$ 34万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 34万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 34万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 34万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 34万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 34万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 34万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 34万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 34万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 34万 - 项目类别:














{{item.name}}会员




